Review: AI in Thrombosis and Hemostasis

Click here for this open-access article that describes AI in thrombosis and hemostasis. (This is the first time we’ve posted about AI). Altememi MA, Favaloro EJ, Islam MZ, Santhakumar AB. Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directions. Clin Chem Lab Med. […]

Comments (0)

Global Hemostasis Assays

Mar 2 2026

george

Bleeding and Thrombosis in Chronic Kidney Disease

Click this open-access article on the adverse outcomes of anticoagulation in chronic kidney disease: Jones A, Swan D, Lisman T, Barnes GD, Thachil J. Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemost. 2024;22:323–36. doi: 10.1016/j.jtha.2023.09.020. PMID: 37778512. Abstract Chronic kidney disease (CKD) is being diagnosed increasingly worldwide. It is often […]

Comments (0)

Anticoagulant Therapy

Mar 2 2026

george

Emicizumab Dosage

Here is an open-access article on current emicizumab dosage: van der Zwet K, de Vos ADW, Cnossen MH, et al; OPTI-CLOT Study Group and SYMPHONY Consortium. Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study. J Thromb Haemost. 2026;24:890–99. doi: 10.1016/j.jtha.2025.10.029. PMID: 41207564. Abstract Background Emicizumab provides effective prophylaxis […]

Bleeding Disorders

March. 2026 Cheat Sheet

Click March 2026 Cheat Sheet for your Fritsma Factor monthly Cheat Sheet that summarizes our February posts and those before. If you’d like a push copy of the Cheat Sheet, updated with links to last month’s posts, complete the brief form at the right. The Cheat Sheet, Quick Questions, posts, informative PowerPoint modules, and more […]

Cheat Sheets

March 2026 QQ: LAC Testing When the Patient is on DOAC

Our March 2026 Quick Question is a poll that asks, “How do you test for LAC when the patient is on a DOAC?” This question arises from the discussion in our 2-19-26 post, “CAP Today: Hemostasis Testing While on DOACs.” Often, the provider requests LAC testing for a thrombosis patient on anticoagulation. While the anticoagulant […]

Comments (0)

Anticoagulant Therapy

Feb 27 2026

george

February 2026 QQ Results: DOAC Names

Our February 2026 Quick Question was a quiz that drew 42 responses. The stem asked, “Which DOAC is a direct thrombin inhibitor?” Your answers: Apixaban: 9 (21%) Betrixaban: 0 Dabigatran: 32 (76%) Edoxaban: 0 Rivaroxaban: 1 (3%) We performed well on this question. No one chose betrixaban, an FXa-directed oral anticoagulant that was withdrawn in […]

Comments (1)

Anticoagulant Therapy

Feb 25 2026

george

Case Series: Emicizumab Therapy in Acquired Hemophilia A

Here is an open-access article describing emicizumab Rx in acquired hemophilia A: Calcaterra I, De Luca C, D’Errico G, et al. Emicizumab in acquired hemophilia A: a real-world case series with patient-level outcome analysis. Semin Thromb Hemost. 2026 doi: 10.1055/a-2788-1642. Epub ahead of print. PMID: 41534873. Abstract Acquired Hemophilia A (AHA) is a rare bleeding […]

Bleeding Disorders

Diagnostic Equity Question: INR is 3.9

This question appeared 2-24-26 on the Diagnostic Equity website: “I’m on warfarin for atrial fibrillation, and my INR today is 3.9. The target range is 2.0–3.0. I haven’t changed my diet or missed any doses. What factors could cause my INR to drift this high unexpectedly, and when does an elevated INR become an emergency?” […]

Comments (0)

Anticoagulant Therapy

Feb 24 2026

george

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

Here is an open-access article contrasting the validity of OSA versus CSA for measuring efanesoctocog alfa (Altuviiio®) spiked into normal plasma: Pipe S, Sadeghi-Khomami A, Konkle BA, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. […]

Factor Assays

JTH Editorial: The Problem With Coagulopathy…

Click here for the open-access editorial Thachil J. The problem with coagulopathy …. J Thromb Haemost. 2022;20:2171-2172. doi: 10.1111/jth.15795. PMID: 35733290. Abstract Coagulopathy is inextricably linked to the field of hemostasis and thrombosis. In the same manner, hemostasis and thrombosis may deal with bleeding and clot formation; coagulopathy also may be connected to bleeding or […]

Comments (0)

Global Hemostasis Assays

All Posts

Review: AI in Thrombosis and Hemostasis

Bleeding and Thrombosis in Chronic Kidney Disease

Emicizumab Dosage

March. 2026 Cheat Sheet

March 2026 QQ: LAC Testing When the Patient is on DOAC

February 2026 QQ Results: DOAC Names

Case Series: Emicizumab Therapy in Acquired Hemophilia A

Diagnostic Equity Question: INR is 3.9

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

JTH Editorial: The Problem With Coagulopathy…

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question